Dr. Michael Mullan, President and CEO of the Roskamp Institute, commented, "The most remarkable results were the clear inhibition of brain inflammation and the degeneration of the spinal cord by anatabine and the accompanying inhibition of the severe paralysis that usually accompanied the model."
Dr. Daniel Paris, the primary author of the article and Head of Research and Development at the Roskamp Institute, added, "The oral administration of anatabine potently reduced the neurological deficits and abrogated the pathological lesions in the spinal cord that are responsible for the development of paralysis in this mouse model of multiple sclerosis (MS). In addition our work also explains the beneficial activity of anatabine in this MS model by showing that this compound prevents the activation of key molecules that orchestrate the propagation of inflammation in the central nervous system and the periphery."
The full title of the study is, "Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine," and can be viewed here: http://dx.plos.org/10.1371/journal.pone.0055392. This study builds upon earlier research conducted by the Roskamp Institute, which showed that the natural alkaloid anatabine displays anti-inflammatory properties and readily crosses the blood brain barrier, suggesting it could represent an important compound for mitigating many types of neuro-inflammatory conditions.
PLOS ONE is an international, peer-reviewed, open-access, scientific journal.Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. About Star Scientific Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism and lifestyle. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also continues to pursue the licensing of the technology behind its proprietary StarCured® curing process and its related products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, and an Executive, Scientific & Regulatory Affairs office in Washington, DC. Contact: Talhia T. Tuck Vice President, Communications and Investor Relations Star Scientific, Inc. (202)887-5100 firstname.lastname@example.org SOURCE Star Scientific, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV